Omico

Homepage: omico.com.au

Alternate name: Australian Genomic Cancer Medicine Centre

ROR: 01f3jhd65

OpenAlex ID: I4405263460

Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing

2024 · Fei Deng, Yi Li, et al. · Nature Communications · 182

Precision medicine: affording the successes of science

2023 · Christine Y. Lu, Vera Terry, et al. · npj Precision Oncology · 73

Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer

2021 · Deepak Singhal, Christopher N. Hahn, et al. · Leukemia · 55

Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?

2022 · Don Husereau, Lotte Steuten, et al. · Healthcare · 10

A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content

2023 · Radwa Sharaf, Dexter X. Jin, et al. · npj Genomic Medicine · 9

Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot

2026 · Paul Lacaze, Jane Tiller, et al. · Nature Health · 7

Implementation of precision medicine in treating non-communicable diseases: a systematic review

2025 · Shuang Liang, Elizabeth Kennedy, et al. · Journal of Translational Medicine · 7

Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program

2024 · Elan Novis, Anthony Glover, et al. · Surgery · 7

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

2026 · Gregory M. Cote, Mason Aberoumand, et al. · Clinical Cancer Research · 4

Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials

2025 · Shuang Liang, Skye McKay, et al. · BMJ Open · 4

82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context

2025 · G. Gaughran, A. Body, et al. · ESMO Open · 2

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma

2025 · Kristen McParland, Eng-Siew Koh, et al. · BMJ Open · 2

Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.

2023 · Subotheni Thavaneswaran, Antony Mersiades, et al. · Journal of Clinical Oncology · 2

Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.

2025 · Scott Spencer, Weicheng Ye, et al. · Journal of Clinical Oncology · 1

P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer

2024 · N. Pavlakis, G. Kichenadasse, et al. · Journal of Thoracic Oncology · 1

POT1 clinical risk management is an open question

2024 · Mandy L. Ballinger, David M. Thomas · European Journal of Human Genetics · 1

88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling

2023 · N. Pavlakis, M. Millward, et al. · Annals of Oncology · 1

Special Session – Molecular Pathology

2023 · : Neurotrophic tropomyosin-receptor kinases 1-3 (NTRK1-3) drive neural development and growth. NTRK 1-3 gene fusions are known oncogenic drivers in rare solid tumours, particularly paediatric gliomas and soft tissue tumours, et al. · Histopathology · 1

Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.

2023 · Maya Kansara, Frank Po-Yen Lin, et al. · Journal of Clinical Oncology · 1

Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.

2022 · Danie Serie, Chad Pickering, et al. · Journal of Clinical Oncology · 1

Population prevalence of high-risk pharmacogenetic configurations in a healthy older Australian reference cohort

2026 · Kosar Hooshmand, Stephen Hughes, et al. · Frontiers in Pharmacology

From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study

2026 · Michail Charakidis, Halli Waran, et al. · Internal Medicine Journal

HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.

2026 · Gregory Gaughran, Vincent Caillet, et al. · Journal of Clinical Oncology

Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature

2026 · Tanya M. Dwarte, Rozanna Alli, et al. · Hereditary Cancer in Clinical Practice

Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation

2026 · Benjamin Koh, Subotheni Thavaneswaran, et al. · JCO Precision Oncology

Works count: 36

Citation count: 763